Thoracic Paravertebral Block in Daytime Laparoscopic Partial Adrenalectomy
Launched by SHANXI BETHUNE HOSPITAL · Aug 21, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a method called thoracic paravertebral block (TPVB) to help manage pain after a specific type of surgery known as laparoscopic partial adrenalectomy, which is performed during daytime surgery. This approach aims to provide effective pain relief while allowing patients to recover quickly and comfortably. The trial will evaluate how well TPVB works for reducing pain after surgery and how it affects the overall recovery experience for patients.
To be eligible for this study, participants need to be between 18 and 70 years old, have a body mass index (BMI) between 18.5 and 30, and be classified as having low to moderate health risks. They should have a specific type of adrenal tumor that is larger than 20mm. Participants can expect to receive either the TPVB treatment or standard pain management, and they will be monitored closely throughout the process to assess their pain levels and recovery. This study is important because it explores a new way to enhance pain management for patients undergoing this surgery, potentially leading to shorter hospital stays and a better overall experience.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 to70 years
- • Body Mass Index (BMI) 18.5 to 30 kg/m²
- • American Society of Anesthesiologists (ASA) grade I to II classification
- • unilateral non-functional adrenal adenoma with a tumor diameter greater than 20mm
- Exclusion Criteria:
- • Patients with peripheral nervous system disease
- • Patients with spinal deformity or surgery
- • Patients with puncture site infection or coagulation abnormalities
- • Patients with history of postoperative nausea and vomiting or allergy to local anesthetics
- • Patients with unstable mental illness or refusal to participate
About Shanxi Bethune Hospital
Shanxi Bethune Hospital is a leading healthcare institution located in Shanxi province, China, dedicated to advancing medical research and enhancing patient care through innovative clinical trials. As a prominent clinical trial sponsor, the hospital is committed to adhering to the highest ethical standards and regulatory guidelines to ensure the safety and efficacy of new treatments. With a multidisciplinary team of experienced researchers and healthcare professionals, Shanxi Bethune Hospital fosters collaboration and utilizes state-of-the-art facilities to facilitate groundbreaking studies that aim to improve health outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taiyuan, Shanxi, China
Patients applied
Trial Officials
Jian-Wen Zhang, MD
Principal Investigator
Shanxi Bethune Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported